Get Your Study Enrolled - Designing Your Impairment Protocol to Prevent Challenges

Development pathways and trial design for liver cirrhosis secondary to NASH

Des informations uniques obtenues à partir de nombreuses études sur la SHNA

Read our lessons learned from 14 MASH trials over the last four years

Focusing on rare kidney diseases with unique collaborative efforts

Explore Fortrea's unique collaborative efforts in researching and addressing rare kidney diseases through advanced methodologies and patient-centric approaches.

SGLT2 inhibitors as renoprotective agents for pediatric patients living with chronic kidney disease

Explore the benefits of SGLT2 inhibitors as renoprotective agents for pediatric patients. Fortrea's blog provides insights into diabetes medication and renal protection.

Unleashing the power of data sharing to transform the drug development landscape for kidney diseases

In 2016, Barbara Gillespie, MD, FASN, Vice President and Therapeutic Head of Nephrology at Fortrea, joined a workgroup with the Kidney Health Initiative (KHI) and U.S. FDA. T

Dialysis trials need to be patient-centric AND dialysis-centric

Objectif : recrutement. Que faut-il éviter d'indiquer dans votre protocole d'étude pour ne pas ralentir le recrutement

Dr. Gillespie goes to Capitol Hill to advocate for rare kidney disease

Dr. Barbara Gillespie, Vice President & Therapeutic Strategy Leader at Fortrea, recently participated in “Rare Kidneys on the Hill Day” on July 25th, joining patients, caregivers, physicians and researchers on Capitol Hill to speak with members of Congress and raise awareness about rare kidney disease (RKD).